You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.
Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.
If the results are validated, investigators believe the method could help diagnose patients without the need for a needle biopsy and with fewer false positives.
Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.
Fulgent and its China-based joint venture are working on a clinical NGS-based test that it says will have better sensitivity than RT-PCR-based kits.
The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.
The company's approach involves using both fluorescence in situ hybridization and next-generation sequencing to provide clinicians with information.
Formerly called OncoCell MDx, the Royal Oak, Michigan-based firm aims to complete a validation study for the prostate cancer risk assay within the next two months.
The clearances pave the way to clinical applications for three of MGI's instruments but the BGI subsidiary faces legal challenges from Illumina in Europe and the US.